Panelist: Policy and Perception
Conversation followed by audience Q+A
How does a vision become reality and what role does public perception play when shaping policy? How does end-of-life care fit into the broader landscape of psychedelic policy reform? Learn from lawyers and advocates, Graham Boyd and Hadas Alterman, and physician, Sunil K. Aggarwal, about the strategies and resources needed to move psychedelic medicines safely into mainstream modalities of care.
More about Hadas
Hadas is an Israeli-American attorney, born in Jerusalem and raised in the San Francisco Bay Area. She has a J.D. from Berkeley Law and a B.A. in Community Studies/Agriculture & Social Justice from the University of California at Santa Cruz. Hadas advises companies on matters of regulatory compliance, policy advocacy, risk management, strategic planning, revenue models, corporate governance, and dispute resolution. Prior to founding PMLG, she worked with a leading cannabis law firm in San Francisco. Hadas has led clients through successful cannabis license applications in California, Maryland, Ohio, and Pennsylvania; served as counsel to equity applicants in Oakland and San Francisco, and works with legacy growers in the Emerald Triangle. Hadas is a former restorative justice practitioner and community organizer dedicated to using the law to expand equitable access to plant medicine. Hadas was the Policy Director of NYMHA, an organization that she co-founded that successfully lobbied for the introduction of a New York bill to decriminalize psilocybin by statute, and is a Board Member of the Psychedelic Bar Association. She also serves on the Equity Subcommittee of the Oregon Psilocybin Advisory Board.